Prevalence of children born small for gestational age with short stature who qualify for growth hormone treatment

BACKGROUND: Recombinant human growth hormone (rhGH) is approved in Europe as a treatment for short children born small for gestational age (SGA) since 2003. However, no study evaluated the prevalence of SGA children with short stature who qualify for rhGH in Europe so far. This study aimed to invest...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ital J Pediatr
Päätekijät: Tamaro, Gianluca, Pizzul, Mariagrazia, Gaeta, Giuliana, Servello, Raffaella, Trevisan, Marina, Böhm, Patricia, Materassi, Paola Manera Ada, Macaluso, Anna, Valentini, Denis, Pellegrin, Maria Chiara, Barbi, Egidio, Tornese, Gianluca
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015030/
https://ncbi.nlm.nih.gov/pubmed/33794966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-021-01026-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia